Amneal Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ (Deficiency) Equity
Consolidated Statement of Changes in Stockholders’ Deficiency
| New PubCo | ||||||||
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock · AdditionalPaid-inCapital · Stockholders’AccumulatedDeficit · AccumulatedOtherComprehensive Loss · Non-ControllingInterests · TotalDeficiency · RedeemableNon-Controlling Interests | ||||||||
| Shares · Amount | ||||||||
| Balance at December 31, 2024 | 309,881 | $3,099 | $560,206 | $(607,062) | $(65,510) | $(245) | $(109,512) | $64,974 |
| Net income (loss) | — | — | — | 72,057 | — | (290) | 71,767 | 56,166 |
| Foreign currency translation adjustments | — | — | — | — | (18,685) | — | (18,685) | — |
| Stock-based compensation | — | — | 31,953 | — | — | — | 31,953 | — |
| Exercise of stock options | 712 | 7 | 1,953 | — | — | — | 1,960 | — |
| Restricted stock unit vesting, net of shares withheld to cover payroll taxes | 3,972 | 40 | (22,318) | — | — | — | (22,278) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | (22,423) | — | (22,423) | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (43,848) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | 1,229 | — | 1,229 | — |
| Other, net of tax of $0 | — | — | — | — | (5,340) | — | (5,340) | — |
| Balance at December 31, 2025 | 314,565 | $3,146 | $571,794 | $(535,005) | $(110,729) | $(535) | $(71,329) | $77,292 |
Consolidated Statement of Changes in Stockholders’ Equity (Deficiency)
| New PubCo | ||||||||
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock · AdditionalPaid-inCapital · Stockholders’AccumulatedDeficit · AccumulatedOtherComprehensive Loss · Non-ControllingInterests · TotalEquity (Deficiency) · RedeemableNon-Controlling Interests | ||||||||
| Shares · Amount | ||||||||
| Balance at December 31, 2023 | 306,565 | $3,066 | $539,240 | $(490,176) | $(32,349) | $230 | $20,011 | $41,293 |
| Net (loss) income | — | — | — | (116,886) | — | (475) | (117,361) | 43,485 |
| Foreign currency translation adjustments | — | — | — | — | (5,788) | — | (5,788) | — |
| Stock-based compensation | — | — | 27,768 | — | — | — | 27,768 | — |
| Exercise of stock options | 397 | 4 | 1,150 | — | — | — | 1,154 | — |
| Restricted stock unit vesting, net of shares withheld to cover payroll taxes | 2,919 | 29 | (7,952) | — | — | — | (7,923) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | (1,168) | — | (1,168) | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (19,804) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | (26,205) | — | (26,205) | — |
| Balance at December 31, 2024 | 309,881 | $3,099 | $560,206 | $(607,062) | $(65,510) | $(245) | $(109,512) | $64,974 |
Consolidated Statement of Changes in Stockholders’ Equity
| Old PubCo · New PubCo | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock · Class B Common Stock · Class A Common Stock · AdditionalPaid-inCapital · Stockholders’AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · Non-ControllingInterests · TotalEquity · RedeemableNon-Controlling Interests | ||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||||
| Balance at December 31, 2022 | 151,490 | $1,514 | 152,117 | $1,522 | — | $— | $691,629 | $(406,183) | $9,939 | $(114,442) | $183,979 | $24,949 |
| Net (loss) income | — | — | — | — | — | — | — | (83,993) | — | 4,728 | (79,265) | 30,543 |
| Foreign currency translation adjustments | — | — | — | — | — | — | — | — | (433) | (626) | (1,059) | — |
| Stock-based compensation | — | — | — | — | — | — | 26,822 | — | — | — | 26,822 | — |
| Exercise of stock options | 148 | 1 | — | — | 15 | 1 | 447 | — | 4 | (2) | 451 | — |
| Restricted stock unit vesting, net of shares withheld to cover payroll taxes | 2,789 | 28 | — | — | 6 | — | 2,594 | — | 77 | (5,069) | (2,370) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | — | — | — | — | (39,248) | (9,249) | (48,497) | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | — | — | (56,684) | (56,684) | (14,199) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | — | — | — | — | (3,366) | — | (3,366) | — |
| Effect of the Reorganization | (154,427) | (1,543) | (152,117) | (1,522) | 306,544 | 3,065 | (182,252) | — | 678 | 181,574 | — | — |
| Balance at December 31, 2023 | — | $— | — | $— | 306,565 | $3,066 | $539,240 | $(490,176) | $(32,349) | $230 | $20,011 | $41,293 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.